1391437-37-8

Basic information

• Product Name: (S)-3-(1-aminoethyl)benzoic acid hydrochloride
• CAS NO: 1391437-37-8
• Molecular Weight: 201.653
• Mol File: 1391437-37-8.mol

Chemical Properties

• CAS DataBase Reference: (S)-3-(1-aminoethyl)benzoic acid hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-(1-aminoethyl)benzoic acid hydrochloride(1391437-37-8)
• EPA Substance Registry System: (S)-3-(1-aminoethyl)benzoic acid hydrochloride(1391437-37-8)

Safety Data

• Hazardous Substances Data: 1391437-37-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-3-(1-aminoethyl)benzoic acid hydrochloride is used as an intermediate in the pharmaceutical industry for the synthesis of various pharmaceutical products. Its role as a building block allows for the creation of a wide range of medications, contributing to the development of new treatments for different medical conditions.
Used in Neurotransmission Research:
In the field of neuroscience, (S)-3-(1-aminoethyl)benzoic acid hydrochloride is utilized as a neurotransmitter, playing a crucial role in the study of neurotransmission and the central nervous system. Its application in research helps to advance our understanding of how nerve cells communicate and the underlying mechanisms involved in various neurological disorders.
Used as a Chiral Building Block:
(S)-3-(1-aminoethyl)benzoic acid hydrochloride is also used as a chiral building block in the synthesis of complex organic molecules. Its unique structure and properties make it a valuable component in the development of new compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

Downstream Products

• 1187930-10-4 3-((S)-1-tert-butoxycarbonylamino-ethyl)-benzoic acid 
• 165949-84-8 3-<1'-<(tert-butyloxycarbonyl)amino>ethyl>benzoic acid 

Relevant articles and documents

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I wherein the variables are as defined herein.

PYRROLO- PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to pyrrolopyrazines compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various disea

Template-constrained cyclic peptides: Design of high-affinity ligands for GPIIb/IIIa

Although peptides adopt a large ensemble of conformations in aqueous solution, they are generally believed to bind to a receptor in a unique conformation. Thus, there is considerable interest in devising methods to restrict the conformational freedom of peptides. One such approach involves tying the amino and carboxy terminal ends of the peptide onto a semirigid template that will lock the intervening peptide backbone into a single conformer or a family of related conformers. This general strategy has been tested using the tripeptide sequence Arg-Gly-Asp (RGD), which binds with low affinity to the platelet glycoprotein IIb/IIIa (GPIIb/IIIa or α(IIb)β3). Mimics of RGD are of interest as antithrombotics because of their ability to inhibit the aggregation of platelets. Prior to this study, other workers (Samanen et al. J. Med. Chem. 1991, 34, 3114-3125) prepared a disulfide- containing cyclic pentapeptide that bound to GPIIb/IIIa with an affinity of approximately 0.1 μM. NMR analysis of the solution conformation of this peptide suggested that replacing the disulfide-containing portion of the cycle with the amino acid m-(aminomethyl)benzoic acid would lead to a more rigid structure. Indeed, introduction of this template into a cyclic RGD- containing peptide resulted in compounds with high affinity for the receptor. Further, systematic inclusion of additional conformational constraints in the form of N(α)- and C(α)-alkyl groups led to a peptide with an affinity of approximately 100 pM for binding to the receptor. This peptide also showed good activity in the platelet aggregation assay at oral doses as low as 0.1 mg/kg.